Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-04-20
2001-08-14
Clark, Deborah J. R. (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S023500
Reexamination Certificate
active
06274717
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterize further genes and their related polypeptides/proteins, as targets for drug discovery.
Membrane-Type Matrix Metalloproteinases (MT-MMPs) are a new family of transmembrane matrix metalloproteinases. At present, there are four human MT-MMPs published in the literature (Sato, H. et al., Nature 370:61-65, 1994; Will, H. and Hinzmann, B. Eur. J. Biochem. 231:602-608, 1995; Takino, T. et al., J. Biol. Chem. 270:23013-23020; Puente, X. S. et al., Cancer Res. 56:944-949, 1996). Recently, a fifth MT-MMP (MT-MMP-5) has been published for mouse (Pei, D., J. Biol. Chem. 274:8925-8932, 1999). Also, a splice variant for human MT-MMP-5 in which the catalytic domain is missing has been patented (U.S. Pat. No. 5,937,508).
MT-MMPs function as both a receptor and as an activator for certain MMPs and serve to localize extracellular matrix proteolysis at the pericellular region. MT-MMPs have been shown to play a role in matastasis and have been identified in numerous carcinomas. An MT-MMP has also been demonstrated to be involved in Alzheimer's Disease where it has been found in white matter microglia (Yamada, T. et al., Acta Neuropathol, 90:421-424, 1995). MT-MMPs may also play a role in the infiltration of inflammatory cells. By Northern Array Grid Analysis, MT-MMP5-L expression was detected in cerebellum and kidney. A multiple tissue Northern blot was also probed for MT-MMP5-L where it was identified in brain, kidney and pancreas. This indicates that these Membrane-Type Matrix Metalloproteinase have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of Membrane-Type Matrix Metalloproteinase family which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, 1) brain-related diseases including diabetes, polycystic kidney disease, renal failure, etc., 2) brain related diseases including Alzheimer's disease, stroke multiple sclerosis, neurodegenerative diseases, etc., 3) cardiovascular diseases including restenosis, myocardial infarction, dilated cardiomyopathy, atherosclerosis, etc., and 4) others such as inflammation and cancer.
SUMMARY OF THE INVENTION
The present invention relates to MT-MMP5-L, in particular MT-MMP5-L polypeptides and MT-MMP5-L polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of 1) kidney-related diseases including diabetes, polycystic kidney disease, renal failure, etc., 2) brain-related diseases including Alzheimer's disease, stroke multiple sclerosis, neurodegenerative diseases, etc., 3) cardiovascular diseases including restenosis, myocardial infarction, dilated cardiomyopathy, atherosclerosis, etc., and 4) others such as inflammation and cancer, hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with MT-MMP5-L imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate MT-MMP5-L activity or levels.
REFERENCES:
patent: 5837508 (1998-11-01), Arnold et al.
D. Pei, “Identification and Characterization of the Fifth Membrane-type Matrix Metalloproteinase MT5-MMP ”Journal of Biological Chemistry, vol. 274, No. 13, pp. 8925-8932 (Mar. 26, 1999).
Database Genbank, Accession No. AJ010262, D. Pei, Mar. 25, 1999.
Database Genbank Accession No. P51512, Takino et al., Jul. 15, 1998.
Database Genbank Accession No. Q98947, Yang et al., Feb. 1, 1997.
Duanqing Pei, “Identification and Characterization of the Fifth Membrane-type Matrix Metalloproteinase MT5-MMP”, The Journal of Biological Chemistry, vol. 274 (13), pp. 8925-8932, (1999).
GenCore Accession No. V69215, Arleth et al, EP 875577-A2 (Jan. 1999).*
GenCore . U.S. Patent 5,837,508, sequence 2, Mar. 1997.*
Pei, D. Journal of Biological Chemistry. 274(13): 8925-8932, Mar. 1999.*
Leube et al. Journal of Cell Biology. 127(6): 1589-1601, Dec. 1994.*
Ledley, F.D. Pharmaceutical Research. 13: 1595-1613, Nov. 1996.*
Branch, A.D. TIBS 23: 45-50, Feb. 1998.*
Verma et al. Nature. 389: 239-242, Sep. 1997.*
Pei, D. Accession No. AJ010262, Mar. 1999.*
Yang et al. Accession No. Q98947, Feb. 1997.*
Takino et al. Accession No. P51512, Oct. 1996.*
Shofuda et al. Accession No. O35548, Jun. 1998.*
Shofuda, K. GenCore Accession No. D85511, Sep. 1997.*
Will et al. GenCore Accession No. Z48481, Aug. 1995.*
Puente et al. Cancer Research. 56(5): 944-9, Mar. 1996.*
Seiki et al. Connective Tissue. 30(4): 313-19, 1998.
Arleth Anthony J.
Arnold Anne Romanic
Li Xiaotong
Zhu Yuan
Chen Shin-Lin
Clark Deborah J. R.
Hecht Elizabeth J.
King William T.
Ratner & Prestia
LandOfFree
Splicing variant of human membrane-type matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Splicing variant of human membrane-type matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Splicing variant of human membrane-type matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2497993